Aeterna Zentaris (NASDAQ:AEZS) Now Covered by Analysts at assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZSFree Report) (TSE:AEZ) in a research note published on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright lowered their target price on shares of Aeterna Zentaris from $28.00 to $15.00 and set a buy rating on the stock in a research report on Monday.

Get Our Latest Research Report on Aeterna Zentaris

Aeterna Zentaris Stock Up 8.1 %

AEZS opened at $1.61 on Tuesday. The stock has a fifty day moving average of $1.98 and a 200-day moving average of $2.55. Aeterna Zentaris has a 12-month low of $1.36 and a 12-month high of $4.00. The firm has a market capitalization of $7.82 million, a P/E ratio of -0.33 and a beta of 1.56.

About Aeterna Zentaris

(Get Free Report)

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.

Featured Articles

Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with's FREE daily email newsletter.